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Abstract
Objective: To examine specific symptom progression patterns and possible dis-
ease staging in Parkinson disease clinical subtypes. Methods: We recently iden-
tified Parkinson disease clinical subtypes based on comprehensive behavioral
evaluations, “Motor Only,” “Psychiatric & Motor,” and “Cognitive & Motor,”
which differed in dementia and mortality rates. Parkinson disease participants
(“Motor Only”: n = 61, “Psychiatric & Motor”: n = 17, “Cognitive & Motor”:
n = 70) and controls (n = 55) completed longitudinal, comprehensive motor,
cognitive, and psychiatric evaluations (average follow-up = 4.6 years). Hierar-
chical linear modeling examined group differences in symptom progression. A
three-way interaction among time, group, and symptom duration (or baseline
age, separately) was incorporated to examine disease stages. Results: All three
subtypes increased in motor dysfunction compared to controls. The “Motor
Only” subtype did not show significant cognitive or psychiatric changes com-
pared to the other two subtypes. The “Cognitive & Motor” subtype’s cognitive
dysfunction at baseline further declined compared to the other two subtypes,
while also increasing in psychiatric symptoms. The “Psychiatric & Motor” sub-
type’s elevated psychiatric symptoms at baseline remained steady or improved
over time, with mild, steady decline in cognition. The pattern of behavioral
changes and analyses for disease staging yielded no evidence for sequential dis-
ease stages. Interpretation: Parkinson disease clinical subtypes progress in clear,
temporally distinct patterns from one another, particularly in cognitive and
psychiatric features. This highlights the importance of comprehensive clinical
examinations as the order of symptom presentation impacts clinical prognosis.
Introduction
Parkinson disease (PD) presents as heterogeneous clinical
manifestations with different combinations of motor, cog-
nitive, and psychiatric symptoms. Differences in symptom
profiles and progression patterns suggest the existence of
PD subtypes, and thus potentially different clinical prog-
noses. Clinical subtypes have been explored previously,
however, these attempts focused on motor symptoms1,2
or used broad metrics for cognitive function3,4 or psychi-
atric function.3,5,6 Furthermore, only a handful of studies
provide follow-up beyond four years,1,7–9 limiting prog-
nostic utility. Therefore, prior subtypes do not account
for the diversity of symptom presentation or longitudinal
progression.
We recently identified three distinct PD clinical sub-
types10: “Motor Only,” featuring mild motor deficits,
“Psychiatric & Motor,” featuring increased psychiatric
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symptoms, and “Cognitive & Motor,” featuring decreased
cognitive function. While cognitive and psychiatric fea-
tures distinguished the subtypes and prior longitudinal
studies demonstrate that cognitive,9,11–13 motor,12,13 and
psychiatric function14,15 worsen over time in PD, the rate
of decline and pattern of symptom progression among
PD clinical subtypes have not been thoroughly explored.
Additionally, though our subtypes differed in mortality
and dementia rates,10 our subtypes may represent disease
stages as suggested by other severity-based subtypes.2,16,17
This study aims to investigate longitudinal symptom pro-
gression within PD clinical subtypes and differences in symp-
tom progression among subtypes. We hypothesize that each
subtype will decline faster in its characteristic symptoms (e.g.,
“Cognitive & Motor” subtype will decline faster in cognitive
function). Furthermore, we hypothesize that the subtypes will
show distinct clinical progression patterns rather than repre-
sent sequential stages of disease severity.
Methods
Study protocol approvals, registrations, and
patient consents
The Washington University in St. Louis Human Research
Protection Office approved this study, and all participants
provided written informed consent.
Participants
All participants come from a larger, longitudinal
study10,18 examining Parkinson disease progression. For
inclusion in the larger study, all participants needed to be
at least 50 years old, have a minimum of 12 years of edu-
cation, and agree to brain donation. PD participants
needed a clinical diagnosis of PD based on the modified
UK PD Society Brain Bank clinical diagnostic criteria,19
with clear motor response to levodopa. For the larger
study, the exclusion criteria included: (1) other neurologic
diagnoses, (2) head injury with loss of consciousness
>5 min or neurologic sequelae, and (3) schizophrenia or
bipolar disorder. In addition, control participants had to
have no first-degree family history of PD, a normal neu-
rological exam, and intact cognition at baseline.
All PD participants in this study received a baseline
subtype classification from a prior analysis10: “Motor
Only,” “Psychiatric & Motor,” or “Cognitive & Motor.”
For inclusion in the present study, PD and controls also
needed (1) a baseline evaluation between January 2006
and September 2015, (2) at least one subsequent evalua-
tion from their baseline visit, and (3) a Clinical Dementia
Rating evaluation (CDR)20 <1 at baseline (i.e., not
demented). Additionally, controls needed a b-amyloid
(Pittsburgh compound B; PiB) PET mean cortical binding
potential <0.1821 for inclusion, reducing the risk for pre-
clinical Alzheimer disease.
The original subtyping analysis10 included 162 PD par-
ticipants. For this study, 14 participants did not have
usable data after the baseline visit (Fig. 1). Thus, these
longitudinal analyses include 148 PD participants
(“Motor Only”: n = 61, “Psychiatric & Motor”: n = 17,
“Cognitive & Motor”: n = 70) and 55 controls who
met all inclusion criteria.
Data collection
All participants completed an initial baseline evaluation
and longitudinal follow-up assessments every 1–3 years
(average number of follow-up visits = 3.7, average time
in study = 4.6 years, range = 1–12 years). At each study
visit, participants completed comprehensive motor, cogni-
tive, and psychiatric evaluations as described below.
162 non-demented PD with Baseline Subtype Classification
Lost to Follow-Up/Withdrew:
“Cognitive & Motor” n = 4
Deceased Prior to Follow-Up:
“Cognitive & Motor” n = 4
Not PD at autopsy:
“Cognitive & Motor” n = 2
ON meds: 
“Motor Only” n = 2
“Cognitive & Motor” n = 2
Longitudinal Study Evaluations (148 PD; 55 CTRLs)
Follow-up every 1-3 years
Average Length of Follow-Up: 4.6 years
Data collected between 2007 – Feb 2020
Figure 1. Consort diagram.
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For the motor assessment, testing occurred in the prac-
tical “OFF” medication state, defined as overnight with-
drawal from PD medications. A movement disorder
specialist rated the Unified Parkinson Disease Rating Scale
motor subscale III (UPDRS3-Total)22 at the study visit or
from video recording.23,24 The specialist’s UPDRS3-Total
rating was broken down into tremor (items 1–7), rigidity
(items 8–12), bradykinesia (items 13–20), and postural
instability and gait disturbance (PIGD; items 23–26)
scores. Importantly, all rigidity scores come from the day
of the study visit from either the specialist or the trained
tester. Raters were trained by a movement disorder spe-
cialist (JSP) to properly score rigidity for consistency
across all testing. This maximized the amount of usable
data.
For cognitive evaluations, participants completed a
comprehensive battery of neuropsychological tests for
each cognitive domain: executive function (Trail Making
Test25; Verbal Fluency- Switching26; Color-Word Interfer-
ence26), visuospatial function (Judgement of Line Orien-
tation27; Spatial Relations Test28), memory (California
Verbal Learning Test- II, short form29; Logical Mem-
ory30), attention (Digit span31; Digit Symbol31), and lan-
guage (Boston Naming test).32 PD participants completed
cognitive assessments while ‘OFF’ medications to avoid
potential medication confounds on performance (i.e., this
provides a more accurate assessment of the participant’s
cognitive function). Additionally, trained raters completed
the CDR with each participant and a collateral source
and scored the CDR sum of boxes (CDR-SB) to provide
a global measure of cognitive function and functional
abilities. All CDR interviews were completed ‘ON’ medi-
cations.
For the psychiatric assessments, participants completed
self-report measures of depression (Geriatric Depression
Scale [GDS])33 and apathy (Frontal Systems Behavior
Scale- Apathy subscale [FrSBe-A]).34 With the partici-
pant’s collateral source, participants also completed the
Neuropsychiatric Inventory Questionnaire (NPIQ)35 as an
overall measure of psychiatric symptoms and severity. All
psychiatric assessments were completed ‘ON’ medications
since the assessments measure function over a period of
time rather than just at the time of the study visit.
Data processing
Standardized scores were computed for each participant
at each visit using the mean and standard deviation of
baseline raw scores (e.g., z-scores) across all participants
in our sample (PD and Control), providing insight into
how each group changes from baseline as well as how PD
subtypes differ from controls. For participants who devel-
oped severe cognitive impairment and could not complete
the entire cognitive battery (e.g., CDR ≥1 at the study
visit, failed the practice portion, or were unable to com-
plete the task), missing test scores were imputed as the
lowest (worst) score possible. All other missing scores
remained blank (i.e., missing). In total, each visit had ele-
ven assessment domains (Motor: bradykinesia, tremor,
rigidity, PIGD; Cognitive: attention, memory, language,
visuospatial, and executive function; Psychiatric: depres-
sion, apathy), representing the original indicator variables
used to define the subtypes10 and three global domains
for motor (UPDRS3 Total), cognitive (CDR-SB), and psy-
chiatric function (NPIQ), making fourteen domains in
total.
Baseline subtypes
PD participants were categorized into one of three sub-
types, previously described in detail in Campbell et al.
(2020).10 Briefly, a latent class analysis (LCA)36 identified
clinical subtypes within PD. LCA is a data-driven,
person-centered analysis that classifies individuals based
on score patterns, rather than classifying individuals based
on relationships among variables. The baseline motor,
cognitive, and psychiatric function scores served as
inputs, with age, sex, and education covariates. Based on
the results of the LCA, three distinct PD clinical subtypes
were evident: (1) “Motor Only,” characterized by mild
motor deficits with intact cognitive and psychiatric func-
tion, (2) “Psychiatric & Motor,” characterized by promi-
nent apathy and depression and moderate motor deficits,
and (3) “Cognitive and Motor,” characterized by
impaired cognitive and motor function but relatively nor-
mal psychiatric function.
Statistical analyses
We used hierarchical linear growth models (HLM) to
investigate longitudinal changes in behavior for PD and
control participants. This class of statistical models
accounts for both individual and group variance. For
these analyses, intercept and slope varied across individu-
als (i.e., random effects), with group status as a predictor
of intercept and slope. Additionally, HLM do not require
participants to have the same number of data points (vis-
its) nor the same length of time between visits. This
increases flexibility with participant inclusion, providing a
more complete picture of between group differences. All
analyses were run in R,37 using the lme4 package,38 and
all figures were generated with ggplot2.39 HLM examined
longitudinal performance changes and between group dif-
ferences (“Motor Only”, “Psychiatric & Motor”, and
“Cognitive & Motor”, controls) for each of the 11 assess-
ment and three global domains. Time between visits was
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calculated as time from a participant’s baseline visit using
the lubridate package.40 Intercept was defined as initial
assessment and time was modeled in years for all fourteen
domains. Similarly, age and symptom duration were cal-
culated as age and years of motor symptoms at baseline
visit. Covariates for all models included: age, sex, and
symptom duration; for the cognitive assessment models,
years of education and number of testing exposures (i.e.,
visits) acted as additional covariates to mitigate potential
practice effects. All controls received a symptom duration
of zero. The key test was the time by group subtype inter-
action. After running models for all assessments, slopes
were extracted from the models using ggeffects41 to assess
the magnitude of change over time for each assessment
and global domain. After extracting each domain’s slopes
from the models, the slopes were converted from stan-
dardized units back to domain specific raw units (e.g.,
actual change in UPDRS3-Total score per year) for CDR-
SB, all motor domains, and all psychiatric domains.
To investigate potential disease staging, we ran the
same growth models (excluding controls) with an added
three-way interaction term for symptom duration, time,
and subtype. We also ran the HLM models with an added
three-way interaction term for age at baseline, time, and
subtype. This additional term tests whether symptom
duration (or age), as indicators of disease severity, signifi-
cantly impacts how the subtypes change over time in a
given domain. To reduce the number of analyses, only
growth models with a significant subtype by time interac-
tion were run with the additional three-way interaction.
Data availability
Data presented in this report will be made available to
research investigators upon request to the corresponding
author.
Results
Consistent with our prior research,10 groups differed on
all baseline demographic and behavioral variables
(Table 1), delineating the differences between the sub-
types.
Longitudinal changes
Table 2 contains the slopes, converted into the domain
specific raw units, for each assessment domain. For com-
plete HLM results for each motor, cognitive, and psychi-
atric assessment and global domain, including
comparisons to controls, see Tables S1–S3, respectively,
and Figure S1. As expected, all subtypes worsen in motor,
cognitive, and psychiatric function compared to controls.
Motor domains
Across subtypes, few differences in motor changes over
time existed (Table 2; Fig. 2A). Of note, the “Motor
Only” subtype worsened significantly faster in rigidity
than the “Cognitive & Motor” subtype, whereas the “Cog-
nitive & Motor” subtype worsened significantly faster in
PIGD than “Motor Only.” The “Psychiatric & Motor”
subtype did not significantly differ from the other two
subtypes on any other motor domains. All three subtypes
worsened in overall motor function (UPDRS3 Total) at
similar rates.
Cognitive domains
The “Cognitive & Motor” subtype worsened significantly
faster than the “Motor Only” and “Psychiatric & Motor”
subtypes in executive function, visuospatial function, and
memory (Table 2; Fig. 2B). For attention, the “Cognitive
& Motor” subtype worsened faster than the “Motor
Only” subtype. The “Cognitive & Motor” subtype also
worsened in overall cognitive function (CDR sum of
boxes) significantly faster than “Motor Only” and “Psy-
chiatric & Motor” subtypes. No other subtype compar-
isons were significant.
Psychiatric domains
The “Psychiatric & Motor” subtype significantly differed
from the other two subtypes on depression ratings
(GDS), showing improvement over time while the other
subtypes reported increased symptoms (Table 2; Fig. 2C).
Furthermore, the “Psychiatric & Motor” subtype reported
relatively stable apathy scores, while apathy ratings
increased for both the “Motor Only” and “Cognitive &
Motor” subtypes. There were no significant subtype dif-
ferences in overall psychiatric function (NPIQ) changes
over time.
Medications
To explore the “Psychiatric & Motor” subtype’s improved
depression (GDS) ratings, we compiled antidepressant
medication data for the baseline visit and categorized par-
ticipants based on antidepressant usage (Yes/No). There
was a significant group difference (v2 (3,203) = 10.6,
p = .01) in antidepressant use at baseline, with more par-
ticipants from the “Psychiatric & Motor” subtype taking
antidepressants (n = 9 of 17) than the “Motor Only” sub-
type (n = 14 of 61; v2 (1,78) = 4.4, p = .04) as well as
compared to controls (n = 8 of 55; v2 (1,72) = 8.6,
p = .003). The “Psychiatric & Motor” subtype and “Cog-
nitive & Motor” subtype did not significantly differ
1698 ª 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
Distinct Progression of Parkinson Disease Subtypes P.S. Myers et al.
(n = 18 of 70; v2 (1,87) = 3.6, p = .06). Despite these dif-
ferences in baseline antidepressant usage, the “Psychiatric
& Motor” subtype reported significantly higher depression
symptoms at baseline (see Table 1).
Next, we analyzed the change in antidepressant usage,
based on data from the baseline and last visit, for the
“Psychiatric & Motor” subtype. There was no significant
change in antidepressant usage between the two time
points (McNemar chi-square: v2 (1,17) = 1.8, p = .18).
Furthermore, GDS slopes for each individual in the “Psy-
chiatric & Motor” subtype were extracted and then com-
pared, showing no significant difference in GDS slopes
based on change in antidepressant medication usage (Wil-
coxon signed-rank: W = 26, p = .42; Fig. 3).
We also explored the impact of dopaminergic medica-
tion on depression in the “Psychiatric & Motor” subtype
as it can impact mood.42–44 Levodopa equivalent daily
dose (LEDD) for baseline and final visits were calcu-
lated.45 LEDD between baseline and last visits did not
significantly change (paired-sample Wilcoxon: W = 54,
p = .30). An interaction between subtype and change in
LEDD (last visit–baseline) was added to the GDS growth
model, showing no significant effect on change in GDS
score over time (p = .23).
Disease staging
To address the possibility that the subtypes reflect more
severe stages of PD, we examined the impact of symptom
duration and baseline age—as proxies for disease severity
—on symptom progression. A three-way interaction for
time, subtype, and symptom duration (or separately,
baseline age) was added to growth models, testing
whether disease severity impacts a subtype’s symptom
progression. Tests for potential effects of disease severity
failed to find any significant effects across motor, cogni-
tive, and psychiatric domains (Table 3). Similarly, the
three-way interaction with age was only significant for
Table 1. Demographic and baseline behavioral data.
Variable Control Motor Only Psychiatric & Motor Cognitive & Motor
N 55 61 17 70
Baseline age (years) 64.07 (9.76)# 63.44 (6.23)¥ 65.08 (8.70) 69.08 (7.66)#,¥
Education (years) 14.67 (2.63)*,# 16.48 (2.38)*,¥ 15.41 (2.35) 15.59 (2.63)#,¥
Sex, f/m (%f) 38/17 (69%)^,# 32/29 (52%)¥ 4/13 (31%)^ 20/50 (29%)#,¥
Symptom duration (years) – 5.93 (4.49)&,¥ 8.46 (4.4)& 7.68 (4.23)¥
Number of testing exposures 3.09 (1.04)*,# 4.25 (1.84)* 3.41 (1.12) 4.23 (1.93)#
Executive function 0.32 (0.5)# 0.38 (0.52)¥ 0.05 (0.7)§ 0.62 (0.9)#,¥,§
Visuospatial function 0.24 (0.6)# 0.32 (0.67)¥ 0.01 (0.91)§ 0.51 (0.98)#,¥,§
Memory 0.32 (0.75)^,# 0.19 (0.64)¥ 0.15 (0.5)^ 0.38 (0.61)#,¥
Attention 0.15 (0.75)*,# 0.5 (0.64)*,¥ 0.2 (0.5)§ 0.62 (0.61)#,¥,§
Language 0.29 (0.62)^,# 0.24 (0.83)&,¥ 0.36 (1.49)^,& 0.35 (1.11)#,¥
CDR-SB 0.0 (0.07)# 0.11 (0.28)¥ 0.44 (0.46) 0.89 (0.96)#,¥
Bradykinesia .32 (0.67)*,^,# 8.15 (4.04)*,&,¥ 10.34 (3.96)^,& 12 (3.52)#,¥
Tremor .18 (0.69)*,^,# 1.82 (2.10)* 2.53 (2.08)^,§ 1.57 (1.65)#,§
Rigidity 0.10 (0.49)*,^,# 3.72 (2.23)*,&,¥ 5.75 (2.61)^,& 6.43 (2.92)#,¥
PIGD 0.22 (0.63)*,^,# 1.67 (1.36)*,&,¥ 2.89 (1.45)^,& 3.44 (1.51)#,¥
UPDRS3-total 0.89 (1.46)*,^,# 16.71 (7.09)*,&,¥ 22.84 (6.03)^,& 25.64 (7.13)#,¥
GDS 1.51 (2.11)^,# 1.10 (0.95)&,¥ 9.31 (2.33)^,&,§ 2.63 (1.78)#,¥,§
FrSBe-A 23.69 (5.87)^,# 22.02 (5.12)&,¥ 35.31 (6.26)^,&,§ 30.19 (6.45)#,¥,§
NPIQ 0.57 (.93)*,^,# 1.79 (2.49)*,&,¥ 3.94 (3.79)^,& 3.5 (3.6)#,¥
LEDD – 666 (502)& 945 (688)& 794 (435)
Baseline antidepressant, Yes/No (%yes) 8/47 (15%)^ 14/47 (23%)& 9/8 (53%)^,& 18/52 (25%)
Values represent mean (SD) except where indicated. CDR-SB, Clinical Dementia Rating evaluation, sum of boxes; PIGD, postural instability and gait
disturbance; UPDRS3-Total, Unified Parkinson Disease Rating Scale, part 3 motor subscale; GDS, Geriatric Depression Scale; FrSBe-A, Frontal Sys-
tems Behavior scale, apathy subscale; NPIQ, Neuropsychiatric Inventory questionnaire; LEDD, Levodopa Equivalent Daily Dose.
All a < 0.05.
*Significant difference between Controls and "Motor Only".
^Significant difference between Controls and "Psychiatric & Motor".
#Significant difference between Controls and "Cognitive & Motor".
&Significant difference between "Motor Only" and "Psychiatric & Motor".
¥Significant difference between "Motor Only" & "Cognitive & Motor".
§Significant difference between "Psychiatric & Motor" and "Cognitive & Motor."
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executive function and memory, indicating age impacted
change in those two domains between the “Cognitive &
Motor” and “Motor Only” subtypes, likely because of the
age difference between the two subtypes.
Discussion
This study aimed to understand longitudinal symptom
changes in PD clinical subtypes, as well as investigate
whether these subtypes represent sequential disease stages.
Our results show distinct motor differences between the
“Motor Only” and “Cognitive & Motor” subtypes, where
“Motor Only” worsens faster in rigidity and “Cognitive &
Motor” worsens faster in PIGD. For cognitive domains,
the “Cognitive & Motor” subtype declines in executive
function, visuospatial function and functional abilities
(CDR sum of boxes) faster than the other two subtypes.
Most interestingly, results for psychiatric domains show
the “Psychiatric & Motor” subtype improves in depressive
symptoms, whereas the other two subtypes worsen in
depressive symptoms. Use of antidepressants cannot
explain this difference. Furthermore, age and symptom
duration do not account for subtype differences in the
longitudinal progression of behavioral features. Not only
do these results provide no evidence for staging across
subtypes, but they also indicate that the three clinical
subtypes progress in temporally unique patterns, such
that the order of symptom manifestation distinguishes the
subtypes from one another and impacts clinical
prognosis.
Subtype progression follows key features
Overall, the subtypes demonstrate similar progressions to
one another in motor symptoms, despite baseline differ-
ences and even after accounting for age, sex, and symp-
tom duration. This contrasts with prior subtypes derived
from motor symptoms.1 While the “Motor Only” subtype
differentiates itself from the “Cognitive & Motor” subtype
in PIGD and rigidity progression, this represents a small
magnitude of change compared to cognitive and psychi-
atric changes.
Indeed, cognitive domains show some of the most
robust differences in symptom progression between sub-
types. Expectedly, the “Cognitive & Motor” subtype dif-
ferentiates itself from the other two subtypes in these
domains, most notably in overall functional abilities
(CDR sum of boxes), highlighting the subtype’s overall
worsening cognitive function. This aligns with our work
showing increased dementia and mortality risk for the
Table 2. Domain specific slopes.
Cognitive domains Executive function¥,§ Visuospatial function¥,§ Memory¥,§ Attention Language CDR-SB¥,§
Motor Only 0.101 0.125 0.024 0.053 0.013 0.192
Psychiatric & Motor 0.195 0.011 0.036 0.095 0.033 0.558
Cognitive & Motor 0.383 0.271 0.168 0.118 0.057 1.087
Motor domains Bradykinesia Tremor Rigidity¥ PIGD¥ UPDRS3-total
MOTOR ONLY 0.568 0.293 0.400 0.326 2.086
Psychiatric & Motor 0.563 0.217 0.313 0.330 2.105
Cognitive & Motor 0.502 0.299 0.037 0.566 1.952
Psychiatric domains GDS&,§ FrSBe-A NPIQ
Motor Only 0.184 1.025 0.178
Psychiatric & Motor 0.391 0.366 0.065
Cognitive & Motor 0.301 1.074 0.344
For motor domains, a positive slope indicates worsening performance. For cognitive domains, a negative slope indicates worsening performance,
except for CDR-SB where, a positive slope indicates worsening cognitive dysfunction. For psychiatric domains, positive slope indicates worsening
severity. For CDR-SB, all motor domains, and all psychiatric domains, the model derived slope was converted to change in domain raw units per
year (e.g., in one year, the "Motor Only" subtype will increase in UPDRS3-Total score by 2.086 points). CDR-SB, Clinical Dementia Rating evalua-
tion, sum of boxes; PIGD, postural instability and gait disturbance; UPDRS3-Total, Unified Parkinson Disease Rating Scale, part 3 motor subscale;
GDS, Geriatric Depression Scale; FrSBe-A, Frontal Systems Behavior scale, apathy subscale; NPIQ, Neuropsychiatric Inventory Questionnaire. For
CDR-SB, all motor domains, and all psychiatric domains, the model-derived slope was converted to domain raw units (e.g., in 1 year, the "Motor
Only" subtype will increase in UPDRS3-Total score by 2.086 points).
All a < 0.05.
&Significant difference between "Motor Only" and "Psychiatric & Motor".
¥Significant difference between "Motor Only" and "Cognitive & Motor".
§Significant difference between "Psychiatric & Motor" and "Cognitive & Motor".
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“Cognitive & Motor” subtype10 and prior research linking
cognitive decline with increased mortality.46,47
Surprisingly, while having stable but elevated apathy,
the “Psychiatric & Motor” subtype differentiates itself
from the other two subtypes in depression in an
unexpected direction (i.e., the subtype’s depression symp-
toms improve), that cannot be explained by antidepres-
sant use at baseline, changes in antidepressant usage while
in the study, or changes in LEDD. Strikingly, Figure 3
shows that all participants in the “Psychiatric & Motor”
Figure 2. Predicted change in each domain. All predictions are based on the HLM growth models. (A) Depicts change over time for each motor
domain. A positive slope indicates worsening performance. (B) Depicts change over time for each cognitive domain for each group. For CDR-SB, a
positive slope indicates worsening cognitive dysfunction. For all other cognitive domains, a negative slope indicates worsening performance. (C)
Depicts change over time for each psychiatric domain. A positive slope indicates worsening severity. UPDRS3-Total, Unified Parkinson Disease
Rating Scale, part 3 motor subscale; CDR-SB, Clinical Dementia Rating evaluation, sum of boxes; PIGD, postural instability and gait disturbance;
GDS, Geriatric Depression Scale; FrSBe-A, Frontal Systems Behavior scale, apathy subscale; NPIQ, Neuropsychiatric Inventory questionnaire.
&significant difference between "Motor Only" and "Psychiatric & Motor"; ¥significant difference between "Motor Only" & "Cognitive & Motor";
§significant difference between "Psychiatric & Motor" and "Cognitive & Motor." All a < 0.05.
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subtype had reduced depression symptoms over time.
While the depression symptom pattern held, regardless of
antidepressant usage, future research should examine the
influence of antidepressant class, duration of use, dosage,
and other treatments (e.g., cognitive behavioral therapy) on
changes in depression. Indeed, to our knowledge, there is
no general consensus on dose equivalents across antide-
pressants. While prior research has looked into this,48 it
concedes assumptions of dose-response relationships that
have not been adequately investigated in PD. Thus, though
the “Psychiatric & Motor” subtype reported greater base-
line antidepressant usage, baseline depression remained ele-
vated. If anything, antidepressant usage reduced differences
in baseline GDS scores between “Psychiatric & Motor” and
the other groups, yet the “Psychiatric & Motor” subtype
still reported elevated levels of depression.
Age and symptom duration cannot explain
subtype progression
The analyses probing disease staging yielded non-
significant results. Neither three-way interaction with age
at baseline or symptom duration at baseline, show consis-
tent, significant interactions between any two subtypes
across a domain category (i.e., motor, psychiatric, or cog-
nitive). While some “Motor Only” individuals may repre-
sent early stages of either of the other two subtypes, the
“Motor Only” subtype had longer survival times to clini-
cal milestones than the other two subtypes,10 symptom
duration and age do not yield meaningful interactions,
and overall symptom progression profiles do not resemble
those of the other two subtypes.
Sequence of clinical manifestations differs
across subtypes
The robust differences in symptom progression and the
lack of evidence for disease staging suggest clear, subtype-
specific temporal patterns in symptom manifestation
(Fig. 4). Most importantly, while the “Motor only” and
“Cognitive & Motor” subtypes report worsening depres-
sion, after 10 years, the levels do not reach that of “Psy-
chiatric & Motor” subtype at baseline. This difference in


















Figure 3. Individual depression changes in the “Psychiatric & Motor” subtype. From baseline and last visit medication information, participants
were categorized as “Initiated Tx” (individuals who started to take antidepressants during the study) and “Stable-Discontinued Tx” (individuals
whose antidepressant usage did not change between baseline and last visit and individuals who stopped taking antidepressants after the baseline
visit). All a < 0.05.
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distinct clinical subtypes, suggesting that the “Psychiatric
& Motor” subtype experiences psychiatric symptoms
before experiencing cognitive decline whereas the opposite
sequence seems true for the “Cognitive & Motor” sub-
types. In contrast, the “Motor Only” subtype worsens in
motor symptoms, but remains relatively unremarkable in
cognitive decline and psychiatric function. Thus, the tem-
poral sequence and rate of progression of clinical features
differs across PD subtypes.
The temporal sequences also emphasize the clinical sig-
nificance for these subtypes. While all subtypes show defi-
cits across motor, cognitive, and psychiatric domains, the
order in which these deficits appear impacts prognosis.
The motor decline in the “Motor Only” subtype resem-
bles motor decline in the other two subtypes, but that
subtype does not have marked decline in cognitive func-
tion and only modest worsening of psychiatric symptoms.
The “Psychiatric & Motor” subtype starts high in depres-
sion and apathy, but improves in depression ratings and
remains relatively stable in apathy and overall psychiatric
function over time. Interestingly, while research suggests
that depression49 and apathy50 produce negative effects
on cognitive function, the “Psychiatric & Motor” subtype
does not demonstrate cognitive dysfunction at baseline.
Rather, despite relatively stable or improved psychiatric
function, the “Psychiatric & Motor” subtype increases in
overall cognitive dysfunction (CDR sum of boxes) over
time. By contrast, the “Cognitive & Motor” subtype dis-
plays cognitive dysfunction at baseline that worsens over
time, however, depression and apathy take >6 years to
significantly increase in severity (i.e., one standard devia-
tion) from baseline. Not only do these patterns emphasize
the difference in progression, they are also incongruous
with research suggesting that depression is an early indi-
cator of dementia,51 as the “Cognitive & Motor” subtype,
not the “Psychiatric & Motor” subtype, has an increased
risk of dementia.10
While the subtypes likely converge in motor, cognitive,
and psychiatric dysfunction at end-stage disease (pre-
morbid), the quality of life in the preceding years will be
sharply impacted by symptom presentation. Therefore, it
is imperative that clinicians conduct a comprehensive
assessment of a patient’s symptoms and their relative
order of onset, as one’s prognosis, particularly time to
dementia and mortality, closely relates to the order in
which different symptoms appear.
Table 3. Disease staging.
Domain Interaction with
Age Symptom duration
Beta p-value Beta p-value
Executive function Time 9 (Psychiatric & Motor vs. Motor Only) 0.02 0.778 0.02 0.859
Time 9 (Cognitive & Motor vs. Motor Only) 0.12 0.028 0.02 0.667
Time 9 (Cognitive & Motor vs. Psychiatric & Motor) 0.14 0.062 0.04 0.693
Visuospatial function Time 9 (Psychiatric & Motor vs. Motor Only) 0.02 0.889 0.01 0.942
Time 9 (Cognitive & Motor vs. Motor Only) 0.04 0.568 0.08 0.294
Time 9 (Cognitive & Motor vs. Psychiatric & Motor) 0.06 0.573 0.07 0.618
Memory Time 9 (Psychiatric & Motor vs. Motor Only) 0 0.947 0.04 0.588
Time 9 (Cognitive & Motor vs. Motor Only) 0.08 0.046 0.05 0.163
Time 9 (Cognitive & Motor vs. Psychiatric & Motor) 0.08 0.132 0.09 0.2
Attention Time 9 (Psychiatric & Motor vs. vs. Motor Only) 0.01 0.789 0 0.937
Time 9 (Cognitive & Motor vs. Motor Only) 0.01 0.855 0.03 0.308
Time 9 (Cognitive & Motor vs. Psychiatric & Motor) 0.01 0.877 0.04 0.548
CDR-SB Time 9 (Psychiatric & Motor vs. Motor Only) 0.01 0.956 0.01 0.979
Time 9 (Cognitive & Motor vs. Motor Only) 0.07 0.636 0.06 0.641
Time 9 (Cognitive & Motor vs. Psychiatric & Motor) 0.08 0.686 0.06 0.827
Rigidity Time 9 (Psychiatric & Motor vs. Motor Only) 0.03 0.699 0.15 0.123
Time 9 (Cognitive & Motor vs. Motor Only) 0.03 0.55 0.03 0.507
Time 9 (Cognitive & Motor vs. Psychiatric & Motor) 0 0.982 0.12 0.213
PIGD Time 9 (Psychiatric & Motor vs. Motor Only) 0.05 0.6 0.12 0.334
Time 9 (Cognitive & Motor Vs. Motor Only) 0.05 0.426 0.09 0.165
Time 9 (Cognitive & Motor vs. Psychiatric & Motor) 0 0.999 0.21 0.095
GDS Time 9 (Psychiatric & Motor vs. Motor Only) 0.12 0.076 0.09 0.267
Time 9 (Cognitive & Motor vs. Motor Only) 0.01 0.859 0.01 0.709
Time 9 (Cognitive & Motor vs. Psychiatric & Motor) 0.12 0.055 0.08 0.34
The three-way interactions between the different subtypes were extracted from the HLM and are shown for symptom duration and age. PIGD,
postural instability and gait disturbances; GDS, Geriatric Depression Scale.
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Strengths and limitations
This study presents evidence for three distinct PD clinical
subtypes whose symptom progression is unique to the
subtype; however, given that average symptom duration is
greater than average time in the study, it remains possible
that individuals could transition from one subtype to
another, particularly near the end stages of the disease
when symptom manifestations may converge. Despite
this, our modeling highlights subtype differences. Even
with the “Psychiatric & Motor” subtype’s small sample
size (n = 17), which limits overall power, we see robust
differences between subtypes. Future research should use
an independent dataset to provide external validation of















































Figure 4. Subtype-specific symptom manifestation patterns. Based on results, motor, psychiatric, and cognitive symptom progressions are shown
for each subtype, illustrating the temporal relationships of symptom manifestations. For the cognitive domain, a negative slope represents worse
performance. For the motor and psychiatric domains, a positive slope represents worse performance.
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these subtypes. Additionally, we acknowledge that the
study lacks a scaled measure of anxiety; however, the
groups do not differ in presence of anxiety at baseline,10
suggesting anxiety may not differentiate subtypes. Our
data also lack comprehensive psychiatric history, thus
limiting our ability to differentiate between lifelong
depression and development of new depression. Despite
this, however, our results show that the presence of
depressive symptoms at baseline is related to differences
clinical progression of PD. Indeed, the ability to investi-
gate the multiple behavioral domains (motor, cognitive,
and psychiatric) remains one of the greatest strengths
of this study. We not only analyzed global domain
measures, but also specific domains within each cate-
gory, providing a comprehensive understanding of dis-
ease progression in PD and the importance of cognitive
and psychiatric features in prognosis. It should be
noted that such understanding may not generalize per-
fectly onto the broader PD patient population from
other geographic regions because the data come from a
single center.
Conclusions
We have demonstrated with our sample that PD clinical
subtypes progress in distinct ways from one another and
found no evidence that these subtypes represent sequen-
tial disease stages (i.e., “Motor Only” progresses to “Psy-
chiatric & Motor”). This accentuates the importance of
including cognitive and psychiatric features when consid-
ering clinical prognosis so that patients and their care-
givers can prepare accordingly.
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Figure S1. Predicted change in each domain. All predic-
tions are based on the HLM growth models. (A) Depicts
change over time for each motor domain. A positive
slope indicates worsening performance. (B) Depicts
change over time for each cognitive domain for each
group. For CDR-SB, a positive slope indicates worsening
cognitive dysfunction. For all other cognitive domains, a
negative slope indicates worsening performance. (C)
Depicts change over time for each psychiatric domain. A
positive slope indicates worsening severity. UPDRS3-
Total, Unified Parkinson Disease Rating Scale, part 3
motor subscale; CDR-SB, Clinical Dementia Rating evalu-
ation, sum of boxes; PIGD, postural instability and gait
disturbance; GDS, Geriatric Depression Scale; FrSBe-A,
Frontal Systems Behavior scale, apathy subscale; NPIQ,
Neuropsychiatric Inventory questionnaire. *significant
difference between Controls and "Motor Only"; ^signifi-
cant difference between Controls and "Psychiatric &
Motor"; #significant difference between Controls and
"Cognitive & Motor"; &significant difference between
"Motor Only" and "Psychiatric & Motor"; ¥significant dif-
ference between "Motor Only" & "Cognitive & Motor";
§significant difference between "Psychiatric & Motor" and
"Cognitive & Motor." All a < 0.05.
Table S1. Hierarchical linear growth models for motor
domains. ¤indicates that values are from models where
controls are the reference group. PIGD, postural instabil-
ity and gait disturbance; UPDRS3-Total, Unified Parkin-
son Disease Rating Scale, part 3 motor subscale.
Table S2. Hierarchical linear growth models for cognitive
domains. ¤indicates that values are from models where
controls are the reference group. CDR-SB, Clinical
Dementia Rating evaluation, sum of boxes.
Table S3. Hierarchical linear growth models for psychi-
atric domains. ¤indicates that values are from models
where controls are the reference group. GDS, Geriatric
Depression Scale; FrSBe-A, Frontal Systems Behavior
Scale, Apathy subscale; NPIQ, Neuropsychiatric Inventory
Questionnaire.
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